LUMINAI·Health-system administrative and operational workflow automation — referral management and intake, prior authorisation, claims and billing exceptions, eligibility verification, document and forms processing. Adjacent to but distinct from classic revenue-cycle management: the unit of work is a WORKFLOW executed end-to-end across systems, not a transaction routed through a clearinghouse.Private

Luminai

ConvictionContext

B2B enterprise software sold to large provider organisations. THE CONTRACT FORM IS NOT DISCLOSED — no retrieved source states whether Luminai prices per workflow, per seat, as a subscription, on a share of recovered dollars, or on shared savings, and the company publishes no pricing. What is established is the BUDGET: administrative and operational labour inside a health system, funded out of collected revenue, framed by the company against roughly $1 trillion of annual US hospital operations spend and administrative activity at 'up to 25% of total healthcare spending' (Series B release). That is Waystar's payer class — paid from money the provider RECOVERS or labour it stops paying for, never from a fee schedule — and it is the most important structural fact here, because canon REG-CODE-001/002 records 26 CPT codes describing clinical AI, only 3 Category I (Jan 2026, Bipartisan Policy Center, secondary), against 1,524 FDA authorisations from FDA's own list (primary) — 508:1 on a mixed basis. No code pays for automating a referral, and none is needed. Architecture is three layers: unstructured-to-structured transformation of faxes, PDFs, charts and handwritten notes; a knowledge graph encoding that system's routing rules, policies, exceptions and institutional judgement; and agentic execution — classify, match patient and provider, route, trigger — escalating to a human whose correction feeds back as training signal.

Revenue

Not disclosed and not verifiable — no revenueARR, bookings or contract value in the Series B release, the 9 Apr 2026 coverage, or on the company's site. Published scale is four unaudited company claims plus a relayed automation rate: 12M+ workflow automations, 7 average use cases per customer, a 48-day average time to value and 5.3x ROI on the company's homepage, and early deployments 'exceeding 80%' automation for certain document types (Forbes, company-attributed). Three of the four are activity. The fourth is an economic claim, and it arrives with no denominator, period, sample or method — the company does not say 5.3x of what — so it cannot be tested and is an assertion to discount rather than evidence to bank. One customer is named. Against Waystar's TTM revenue of $1.21B, +19.2% to 30 Jun 2026 (CF-WAY-16), this is not a smaller version of the same disclosure — it is a different regime.

Rev growth

Not disclosed. None of the published metrics is a flow: '12 million+ workflow automations' carries no period and no comparativeso it cannot be differenced, and the per-customer and time-to-value averages are undated stocks with no baseline. The only dated trajectory is capital — ~$3.4M seed, $16M Series A (Jun 2022), $38M Series B (Apr 2026) — and the near-four-year gap between priced rounds is itself the most informative growth datum available.

Gross margin

Not disclosedstructurally below Waystar's 68-69% (CF-WAY-16) and below pure SaaS. Delivery is document-heavy inference — OCR and vision over faxes, handwriting and scans, then multi-step agentic reasoning — metered per document and per decision rather than per seat. Larger still, human-in-the-loop escalation is a real cost of goods: at '>80% automation for certain document types', up to one in five items needs a person, and the qualifier concedes the platform average is lower. Whether that person sits on Luminai's payroll or the customer's is undisclosed and decides the answer.

Op margin

Not disclosedpresumed deeply negative. Series B proceeds are earmarked for product, engineering and DEPLOYMENT headcount and more enterprise customers — spending ahead of revenue by the company's own description. A 48-day time to value is a services-assisted number, and services-assisted implementation is the classic drag on early health-IT operating margin.

Capex intensity

Low on the balance sheet — asset-lightcloud inference as opex, no owned compute. The economically real investment is expensed: the per-customer knowledge-graph build encoding one system's routing rules and exceptions. It is only partly reusable across customers, which is why 48 days is a claim worth making — and why that reusability, an internal fact no outsider can observe, decides whether unit economics ever resolve toward software.

Valuation

n/aprivate) — never listed, no exchange price. Unlike Hippocratic (~$3.5B), Ambience (~$1.25B) or OpenEvidence ($12B), NO POST-MONEY HAS BEEN DISCLOSED AT ANY LUMINAI ROUND — not the ~$3.4M seed, the $16M Series A of Jun 2022, or the $38M Series B of 9 Apr 2026; the primary release, Forbes, MedCity News, HIT Consultant and MobiHealthNews all give a round size and a syndicate and no price. No valuation is inferred from the raise: $38M is consistent with post-moneys spanning roughly $150M–$600M on dilution alone, and canon's cautionary case is on file (Sword Health's $4B mark set by a $40M round, 13.5 months stale, CM-COH-05). Luminai therefore cannot be added to canon's private cohort of six disclosed marks (~$33.05B of last-round marks dated Jun 2025 to May 2026, CM-COH-04) — it has no mark to add.

The read

Where our coverage leans

Coverage leans bullish

Members only

Full financial intelligence for Luminai

Earnings, margins & COGS, the income-statement breakdown, SWOT, moats & dependencies, the supplier–customer ecosystem graph, top signals & trends, and the valuation range.

Income statement & margin structure
SWOT, moats & dependency map
Supplier–customer ecosystem graph
Signals, trends & valuation range

See plans

Not financial advice — analyst work product for a qualified professional.